Rapid Dose Therapeutics (XCNQ:DOSE) EV-to-EBIT : -8.73 (As of May. 09, 2024)

Rapid Dose Therapeutics EV-to-EBIT Chart

Rapid Dose Therapeutics Annual Data
	Trend	Sep14	Sep15	Sep16	Sep17	Sep18	Feb19	Feb20	Feb21	Feb22	Feb23
EV-to-EBIT		Get a 7-Day Free Trial					-5.16	-3.54	-11.38	-3.28	-3.08

Rapid Dose Therapeutics Quarterly Data
	Feb19	May19	Aug19	Nov19	Feb20	May20	Aug20	Nov20	Feb21	May21	Aug21	Nov21	Feb22	May22	Aug22	Nov22	Feb23	May23	Aug23	Nov23
EV-to-EBIT	Get a 7-Day Free Trial															-1.17	-3.08	-5.69	-6.21	-6.33

Competitive Comparison of Rapid Dose Therapeutics's EV-to-EBIT

For the Biotechnology subindustry, Rapid Dose Therapeutics's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Rapid Dose Therapeutics's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Rapid Dose Therapeutics's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Rapid Dose Therapeutics's EV-to-EBIT falls into.

Rapid Dose Therapeutics EV-to-EBIT Calculation

Rapid Dose Therapeutics's EV-to-EBIT for today is calculated as:

Rapid Dose Therapeutics's current Enterprise Value is C$26.73 Mil.
Rapid Dose Therapeutics's EBIT for the trailing twelve months (TTM) ended in Nov. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-3.06 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Rapid Dose Therapeutics  (XCNQ:DOSE) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Rapid Dose Therapeutics's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Nov. 2023 is calculated as:

Rapid Dose Therapeutics's Enterprise Value for the quarter that ended in Nov. 2023 was C$19.38 Mil.
Rapid Dose Therapeutics's EBIT for the trailing twelve months (TTM) ended in Nov. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-3.06 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Rapid Dose Therapeutics EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Rapid Dose Therapeutics's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Rapid Dose Therapeutics (XCNQ:DOSE) Business Description